NCT00806806CompletedPhase 1
A Phase 1 Randomized, Single-blind, Sequential Cohort, Crossover Study to Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers
Pacira Pharmaceuticals, Inc1 site in 1 country128 target enrollmentStarted: October 2008Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Pacira Pharmaceuticals, Inc
- Enrollment
- 128
- Locations
- 1
- Primary Endpoint
- time to onset of action
Study Overview
Brief Summary
Given as a single perioperative injection, SKY0402 could provide adequate, continuous, and extended pain relief that could greatly simplify postoperative pain management, reduce the need for repeated administration, and minimize episodes of breakthrough pain.
Detailed Description
Subjects will be given either SKY0402 or placebo in response to a noxious stimulus, and the time to onset will be recorded.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Supportive Care
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 55 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subjects eligible for study entry will meet the following criteria:
- •Male or female, ages at least 18 years and not over 55 years.
- •Body mass index (BMI) within the range 20.0 to 30.0 kg/m2, inclusive.
- •Applies to females only: Female subjects of childbearing potential with a nonsterilized male sexual partner must agree to use a hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device beginning > 30 days prior to the first dosing and continuing until > 7 days after the end of the study. Female subjects who are postmenopausal must have been postmenopausal for > 1 year if they wish not to use contraceptives.
- •Good general health, evidenced by a lack of significantly abnormal findings on medical history and screening assessments.
- •Pain intensity score of > 30 mm on a VAS after incision and application of an 18% acetic acid solution to nontreated skin (i.e., not infiltrated with any test or control article) at Screening.
- •Able and willing to comply with all study visits and procedures, including returning as scheduled for the second treatment visit.
- •Able to speak, read, and understand the language of the ICF, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
- •Willing and capable of providing written informed consent.
Exclusion Criteria
- •A subject will not be eligible for the study if he or she meets any of the following criteria:
- •A history of hypersensitivity to amide type local anesthetics.
- •Pregnancy, nursing, or planning to become pregnant during the course of the study.
- •Any current conditions that might interfere with pain assessments, including current pain.
- •Conditions of the skin or neurological abnormalities that might alter pain sensitivity. These include excessive scarring, burns, skin grafts, and trauma. Tattoos are permitted.
- •A history of keloid formation.
- •A coagulopathy or use of medications that might enhance bleeding.
- •Use of any of the following medication within the times specified before study drug administration:
- •Long-acting opioid mediations within 3 days.
- •Any opioid medication within 24 hours.
- •Any analgesic medication within 12 hours.
- •Consumption of alcohol within 24 hours before either treatment visit.
- •Any condition that, in the opinion of the Investigator, renders a subject unsuitable for participation in the study. NOTE: The specific reason(s) for exclusion will be documented in the Screening Log.
- •Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
- •Minor deviations in eligibility criteria are permitted if approved by the Pacira Medical Monitor in agreement with the Investigator prior to dosing.
Arms & Interventions
Placebo
Placebo Comparator
Intervention: Placebo (Drug)
SKY0402
Experimental
Intervention: SKY0402 (Drug)
Outcomes
Primary Outcomes
time to onset of action
Time Frame: 15 minutes
Secondary Outcomes
- time to onset(bewteen 15 and 30 minutes)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing BunionectomyPostoperative PainNCT01206595Pacira Pharmaceuticals, Inc58
Completed
Phase 2
Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia RepairInguinal HerniaNCT01203644Pacira Pharmaceuticals, Inc76
Active, not recruiting
Not Applicable
Long-term Follow-up Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as ReferenceInfertilityNCT06321107Changchun GeneScience Pharmaceutical Co., Ltd.158
Completed
Phase 2
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial CarcinomaEndometrial CancerNCT04205630Byondis B.V.64
Terminated
Phase 1
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial CancersCancerNCT03138408AbbVie24